Short Interest in Tenax Therapeutics, Inc. (NASDAQ:TENX) Decreases By 69.4%

Tenax Therapeutics, Inc. (NASDAQ:TENXGet Free Report) was the recipient of a significant decrease in short interest during the month of August. As of August 31st, there was short interest totalling 10,700 shares, a decrease of 69.4% from the August 15th total of 35,000 shares. Based on an average daily volume of 614,700 shares, the short-interest ratio is presently 0.0 days.

Tenax Therapeutics Stock Performance

NASDAQ:TENX traded down $0.01 during trading hours on Wednesday, reaching $0.28. 51,065 shares of the company were exchanged, compared to its average volume of 1,948,645. Tenax Therapeutics has a 52-week low of $0.25 and a 52-week high of $7.40. The stock has a 50 day simple moving average of $0.32 and a 200 day simple moving average of $0.37.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tenax Therapeutics stock. Virtu Financial LLC acquired a new stake in Tenax Therapeutics, Inc. (NASDAQ:TENXFree Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 84,361 shares of the specialty pharmaceutical company’s stock, valued at approximately $39,000. Virtu Financial LLC owned approximately 0.38% of Tenax Therapeutics at the end of the most recent reporting period. 1.67% of the stock is owned by institutional investors and hedge funds.

About Tenax Therapeutics

(Get Free Report)

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

Read More

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with's FREE daily email newsletter.